However, a study from the MD Anderson Cancer Center showed that allogeneic HSCT reduced the risk of relapse and improved both RFS and OS, regardless of the FLT3 allelic ratio and NPM1 status, as compared to the non-transplant group among the 227 FLT3-mutated AML patients [54]. The gene discussed is FLT3; the disease is acute myeloid leukemia.